In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
Opinion|Podcasts|June 2, 2025
Addressing Iron Deficiency Anemia in Women’s Health: Insights for the OB/GYN Practice
Author(s)Steven Fein, MD, MPH, Ashley Benson, MD
Panelists discuss how understanding the causes of iron deficiency in pregnancy, selecting appropriate supplementation strategies, and collaborating between obstetrician-gynecologists and hematologists are crucial for effective management and ensuring optimal care for pregnant women.
Advertisement
Advertisement
Related to this article
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
Trending on HCPLive
1
Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD
2
The Liver Keeps the Score: Americans Are Drinking Less, but Alcohol-Associated Liver Disease May Lag
3
EADV Congress 2026: Day 3 Recap—5 Headlines to Know
4
AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD
5